 - Exposure to sensitive or narrow therapeutic range substrates of the drug metabolizing enzymes CYP2C8, CYP2C9, CYP2C19, CYP2D6 or the drug transporters Pgp MDR1, BCRP, OATP1B1, OATP1B3, OCT1 and OCT2 within the appropriate wash-out period a minimum of 5 x reported elimination half-life before the first dose of study treatment see Appendix B 